BlossomHill Therapeutics, Inc. (BLSM)
BlossomHill Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.
With each of our programs, we combine a deep understanding of disease and protein dynamics with our structure-based rational drug design expertise to identify the specific structural liabilities that limit existing therapies or approaches, and then design novel chemical scaffolds to directly address these limitations.
Our most advanced product candidate, BH-30643, is an OMNI-EGFR inhibitor being evaluated in SOLARA, a global Phase 1/2 clinical trial in patients with EGFR-mutant NSCLC.
BlossomHill Therapeutics, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | J. Jean Cui, Ph.D. |
Contact Details
Address: 10255 Science Center Drive, Suite 200 San Diego, CA 92121 United States | |
| Phone | (858) 732-3880 |
| Website | bhtherapeutics.com |
Stock Details
| Ticker Symbol | BLSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1839970 |
| Employer ID | 85-1578711 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| J. Jean Cui, Ph.D. | President, Chief Executive Officer, Director |
| Y. Peter Li, Ph.D., MBA | Executive Chairman |
| Jason Keyes, MBA | Chief Financial Officer, Executive Vice President |
| Vincent Liptak, J.D., Ph.D., MBA | General Counsel, Executive Vice President |
| Geoff Oxnard, M.D. | Chief Medical Officer, Executive Vice President |
| Sundeep Agrawal, M.D. | Director |
| Bihua Chen, MBA | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
| Sheila Gujrathi, M.D. | Director |
| John Schmid, MBA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 11, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 24, 2026 | DRS | [Cover] Draft Registration Statement |
| Dec 10, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 2, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 1, 2021 | D | Notice of Exempt Offering of Securities |
| Jan 11, 2021 | D | Notice of Exempt Offering of Securities |